Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematologic manifestations of malignancy.

R A Johnson1, G D Roodman

  • 1Wilford Hall U.S.A.F. Medical Center, San Antonio, Texas.

Disease-A-Month : DM
|November 1, 1989
PubMed
Summary

Hematologic dysfunction is common in cancer patients, with anemia being most frequent. Understanding these blood-related issues is crucial for effective cancer care and management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.

Leukemia·2017
Same author

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.

Leukemia·2016
Same author

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.

Blood cancer journal·2016
Same author

Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.

Leukemia·2015
Same author

Pathogenesis of myeloma bone disease.

Leukemia·2008
Same author

In vivo impact of a 4 bp deletion mutation in the DLX3 gene on bone development.

Developmental biology·2008

Area of Science:

  • Oncology
  • Hematology

Background:

  • Hematologic dysfunction is a frequent complication in patients with malignancy.
  • Anemia, leukocytosis, thrombocytosis, and coagulation abnormalities are common.
  • These issues arise from malignancy itself, treatments, or related conditions.

Purpose of the Study:

  • To review the spectrum of hematologic dysfunctions in cancer patients.
  • To highlight the importance of recognizing these complications for clinical management.

Main Methods:

  • Literature review of hematologic complications in malignancy.
  • Synthesis of information regarding causes, manifestations, and clinical significance.

Main Results:

  • Anemia is prevalent, caused by blood loss, marrow involvement, therapy, or chronic disease.
  • White blood cell count elevations, monocytosis, and thrombocytosis are common.
  • Coagulation abnormalities can lead to thrombotic or bleeding events.

Conclusions:

  • Hematologic complications are diverse and significantly impact cancer patient care.
  • Clinicians must possess a thorough understanding of these potential issues.

Related Experiment Videos